Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Complement activation in progressive renal disease
Amy Fearn, Neil Stephen Sheerin, Institute of Cellular Medicine, Newcastle University, NE2 4HH Tyne and Wear, United Kingdom
Author contributions: Fearn A and Sheerin NS contributed to the preparation of this manuscript.
Conflict-of-interest: The authors report no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Amy Fearn, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH Tyne and Wear, United Kingdom. amy.fearn@ncl.ac.uk
Telephone: +44-0191-2227146
Received: September 2, 2014
Peer-review started: September 4, 2014
First decision: October 17, 2014
Revised: November 14, 2014
Accepted: December 3, 2014
Article in press: December 10, 2014
Published online: February 6, 2015
Processing time: 157 Days and 17 Hours
Peer-review started: September 4, 2014
First decision: October 17, 2014
Revised: November 14, 2014
Accepted: December 3, 2014
Article in press: December 10, 2014
Published online: February 6, 2015
Processing time: 157 Days and 17 Hours
Core Tip
Core tip: Complement activation occurs in progressive chronic kidney disease and may contribute to the chronic inflammation that is characteristically found in the kidney. It is therefore possible that inhibiting complement activation would reduce inflammation, lead to reduced fibrosis and preservation of renal function.